Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02082626 · ClinicalTrials.gov registry record · Phase 1
Study of Eribulin in Children With Cancer to Determine Safety
A Phase 1 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02082626: Clinical Trial Phase 1 study, sponsored by University of Oklahoma.
NCT02082626 is a Phase 1 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02082626, a Phase 1 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigators will be monitoring the children on this study for the safety of the treatment and levels of eribulin in the blood after treatment. The investigators will also study the effect of the agent on the cancer.
Primary Outcome
The dose that does not cause dose limiting toxicity during the first cycle in more than 1 of 6 subjects
Interventions
- DRUG Eribulin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-02-01 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Why NCT02082626 stopped before completion
NCT02082626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Eribulin mesylate is the first listed.
NCT02082626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02082626 about?
NCT02082626 is a clinical study titled "Study of Eribulin in Children With Cancer to Determine Safety". This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigator...
What is the current status of trial NCT02082626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-02-01. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02082626?
The interventions under investigation include: Eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT02082626?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02082626's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI